This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Dr Gouws added that WHO was the only regulatory authority to have performed inspections of Chinese manufacturers of Covid-19 vaccines during the pandemic. Dr Gouws indicated that many of the Covid-19 vaccine manufacturers in India had also been inspected by WHO and a similar information sharing approach had been undertaken by WHO.
197-217 SG Chou, AK Soper, S Khodadadi, JE Curtis, S Krueger, MT Cicerone, A Fitch, E Shalaev (2012). In : Lyophilized Biologics and Vaccines: Modality-Based Approaches. Current research interests include: Role of water in solid-state chemical stability of proteins and small molecules Advanced analytical methods (e.g.,
Dr Gouws added that WHO was the only regulatory authority to have performed inspections of Chinese manufacturers of Covid-19 vaccines during the pandemic. Dr Gouws indicated that many of the Covid-19 vaccine manufacturers in India had also been inspected by WHO and a similar information sharing approach had been undertaken by WHO.
During the pandemic, the pharmaceutical industry faced challenges in the production of COVID-19 therapeutics and vaccines to meet global demand, as well as mitigation of drug shortages for non-COVID-19-related products, without compromising product quality or patient safety. Published May 2012. Published 2008. 5 (May 2022): 1232–1244.
2 , 16 , 17 , 18 One example is the switching of tributyltin azide with sodium azide and dimethyl formamide by Zhejiang Huahai Pharmaceuticals (ZHP) in 2012 to reduce waste and to increase yield in the production of angiotensin II receptor blockers, resulting in the formation of N-nitrosodimethylamine (NDMA), a known carcinogenic impurity.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content